Quick Answer
Dermata Therapeutics, Inc. reported Common Stock Shares Outstanding of 2.66 million shares for the year ending 2025.
- Dermata Therapeutics, Inc. showed an increase of +956.8% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Dermata Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: 1.91 million shares | Q3 2021: 8.33 million shares | Q1 2022: 8.33 million shares | Q2 2022: 10.10 million shares | Q3 2022: 12.10 million shares | Q1 2023: 2.39 million shares | Q2 2023: 3.19 million shares | Q3 2023: 3.19 million shares | Q1 2024: 6.66 million shares | Q2 2024: 693,175 shares | Q3 2024: 1.68 million shares | Q1 2025: 6.03 million shares | Q2 2025: 637,757 shares | Q3 2025: 844,457 shares.
- Over the full 5 years of available data (2021 to 2025), Dermata Therapeutics, Inc.'s Common Stock Shares Outstanding has declined by 68.1%.
- Historical annual values: Fiscal year 2025: 2.66 million shares | Fiscal year 2024: 251,725 shares | Fiscal year 2023: 261,998 shares | Fiscal year 2022: 770,115 shares | Fiscal year 2021: 8.33 million shares.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: